# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Mankiller (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML052-SYN
- Date: 2026-05-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rena Hawkfeather-Lindqvist, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review on pyridostigmine and prednisone. **S**

## History of present illness

Ms. Mankiller returns six weeks after starting prednisone, which reached 40 mg each morning two weeks ago. She had no worsening as the dose rose. Her eyelids droop only late in the evening now, double vision is rare, and she can brush her hair and finish meals without resting. She sleeps less well and feels hungrier, and has gained about 2 kg. She has had no infections. The screening tests drawn at the last visit were normal: TPMT activity normal, hepatitis B surface antigen and core antibody negative with immunity from vaccination, and the tuberculosis blood test negative. She saw the thoracic surgeon two weeks ago, and a robotic thymectomy is planned in five weeks. Her home blood pressure readings average 118/76. She drinks about 2.5 liters of water a day. **S**

| Element | Detail |
|---|---|
| Prednisone | 40 mg each morning for two weeks; no early worsening |
| Strength | MG-ADL 3, from 7 |
| Screening | TPMT normal; hepatitis B and tuberculosis screens negative |
| Thymectomy | Robotic thymectomy planned in five weeks |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Mild ptosis late in the evening; double vision rare |
| Constitutional | Positive | Weight up about 2 kg; hungrier on prednisone |
| Psychiatric | Positive | Sleeps less well on prednisone; mood steady; PHQ-2 score 1 |
| Respiratory | Negative | No breathlessness; cough strong |
| Integumentary | Negative | No infections or skin problems |

5 systems reviewed. **S**

## Current medications

- Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before meals **S**
- Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mg **S**
- Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) daily **S**
- Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with food **S**
- Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet daily **S**
- Sulfamethoxazole 800 mg / trimethoprim 160 mg oral tablet, one tablet three times a week, while prednisone is 20 mg or more with azathioprine **S**
- Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/82 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 63.9 kg; BMI 24.1 kg/m². All vital signs are synthetic.

Hemoglobin: 13.2 g/dL; White cell count: 10.4 10*3/uL; Platelets: 284 10*3/uL; Potassium: 4 mmol/L; Glucose: 104 mg/dL (high); Creatinine: 0.76 mg/dL; eGFR (CKD-EPI 2021): 105 mL/min/1.73 m²; ALT: 20 U/L; Forced vital capacity (seated): 3.48 L; Femoral neck Z-score (DXA): -0.4; Lumbar spine Z-score (DXA): -0.7; PHQ-2: 1. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.8 g/dL at baseline, 13.2 g/dL at this visit **S**
- White cell count: 6.9 10*3/uL at baseline, 10.4 10*3/uL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 284 10*3/uL at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4 mmol/L at this visit **S**
- Glucose: 88 mg/dL at baseline, 104 mg/dL (high) at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 0.76 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 102 mL/min/1.73 m² at baseline, 105 mL/min/1.73 m² at this visit **S**
- ALT: 18 U/L at baseline, 20 U/L at this visit **S**
- Forced vital capacity (seated): 3.3 L at baseline, 3.48 L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 128/82 mm Hg; weight 63.9 kg |
| Eyes | No ptosis after one minute of upgaze; eye movements full |
| Neurological | Neck flexion 5 of 5; arm abduction held for 90 seconds; counts to 50 without a nasal voice |
| Respiratory | FVC 3.48 L |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Generalized myasthenia gravis, improving** (G70.00). Much improved on prednisone 40 mg and pyridostigmine; MG-ADL 3. Stable enough for thymectomy in five weeks. **S**
   - Azathioprine 50 mg daily from today, 100 mg daily after two weeks, then 150 mg (about 2.3 mg/kg).
   - Prednisone stays at 40 mg until after the thymectomy; the taper will start once she has recovered.
   - Continue pyridostigmine 60 mg four times daily.
2. **Starting azathioprine** (Z79.624). TPMT activity normal; the steroid-sparing effect takes several months. **S**
   - Blood count and liver tests at two, four and six weeks, then every three months.
   - Report fever, sore throat, unusual bruising, yellow skin or dark urine.
3. **Glucocorticoid therapy** (Z79.52). Glucose 104 mg/dL non-fasting; blood pressure 128/82 mm Hg; weight up 2.3 kg; white cells 10.4, as prednisone causes. DXA Z-scores normal (femoral neck -0.4, spine -0.7), so fracture risk is low; calcium and vitamin D continue. **S**
   - Trimethoprim-sulfamethoxazole three times a week while prednisone is 20 mg or more with azathioprine.
   - Eye examination within the year.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | MG-ADL score | Every visit | Completed today | 3, down from 7 |
| Imaging | Forced vital capacity | Every visit while on dose changes | Completed today | 3.48 L, up from 3.25 |
| Examination | Myasthenic crisis warning signs and early steroid worsening | Every visit | Completed today | None during the rise to 40 mg |
| Laboratory | Blood count before azathioprine | Baseline, then every one to two weeks for two months | Completed today | Hemoglobin 13.2 g/dL; white cells 10.4 on prednisone; platelets 284 |
| Laboratory | Chemistry: potassium, glucose, creatinine, eGFR and ALT | Baseline before azathioprine and periodically on glucocorticoids | Completed today | Potassium 4.0 mmol/L; glucose 104 mg/dL non-fasting; creatinine 0.76 mg/dL; eGFR 105; ALT 20 U/L |
| Laboratory | TPMT, hepatitis B and tuberculosis screening | Before azathioprine | Completed today | TPMT activity normal; hepatitis B surface antigen and core antibody negative, surface antibody positive; interferon-gamma release assay negative |
| Imaging | Bone density (DXA) | Soon after starting glucocorticoids expected to last more than three months | Completed today | Femoral neck Z-score -0.4; lumbar spine Z-score -0.7 |
| Examination | Blood pressure and weight | Every visit | Completed today | 128/82 mm Hg in clinic; home average 118/76; weight up 2.3 kg |
| Examination | Eye examination on glucocorticoids | Yearly | Due | Within the year, at the Cherokee Nation eye clinic |
| Medication safety | Pneumocystis prophylaxis | While prednisone is 20 mg or more with a second immunosuppressant | Completed today | Trimethoprim-sulfamethoxazole three times a week from today; potassium will be watched |
| Medication safety | Medicines that can worsen myasthenia gravis | With every new prescription | Completed today | Surgical and anesthesia teams told; the list sent with the thymectomy referral |
| Survey | Depression screen (PHQ-2) and sleep | At intervals | Completed today | PHQ-2 score 1; sleep shorter on prednisone |
| Referral | Thoracic surgery | Once | Completed today | Seen two weeks ago; robotic thymectomy planned in five weeks |
| Self-management | Home blood pressure and water intake | Every visit | Completed today | Home readings about 118/76; water about 2.5 liters a day |

## Goal progress

- A confirmed diagnosis and treatment plan within three weeks. Outcome by 2026-03-23: AChR antibodies, nerve stimulation, chest CT and kidney ultrasound done; generalized MG diagnosed and treatment begun at two weeks. **S**
- Minimal manifestation status (MG-ADL 0 to 1) within a year, with prednisone at 7.5 mg or less. In progress; target 2026-10-12. **S**
- No myasthenic crisis, and she knows the warning signs and the medicines to avoid. In progress; target 2026-10-12. **S**
- Kidney health: eGFR and urine albumin yearly, home blood pressure 110/75 mm Hg or lower if it rises above 130/85, 2 to 3 liters of water a day, and no NSAIDs. In progress; target 2026-10-12. **S**
- Return to full-time work for the Cherokee Nation. In progress; target 2026-10-12. **S**

## Medication changes

- Started: Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) daily **S**
- Started: Sulfamethoxazole 800 mg / trimethoprim 160 mg oral tablet, one tablet three times a week, while prednisone is 20 mg or more with azathioprine **S**

## Guideline basis

- Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020), Myasthenia Gravis Foundation of America task force (Neurology)
- Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016), Myasthenia Gravis Foundation of America task force (Neurology)
- KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025), Kidney Disease: Improving Global Outcomes (KDIGO)
- Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022), American College of Rheumatology

## Follow-up

- Blood count and liver tests at two, four and six weeks at the Cherokee Nation clinic near her home. Thymectomy in five weeks. Review here five weeks after surgery. **S**
- Next scheduled visit 2026-07-13: review five weeks after thymectomy: recovery, pathology, azathioprine monitoring, the prednisone taper, and kidney care. **S**
